Integrative Traditional Chinese and Western Medicine for Breast Cancer
Official title: Clinical Observational Studies: Breast Cancer Treatment by Traditional Chinese and Western Medicine
Run by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation · NCT07096180 · Data updated 2026-11-12
This project will see if adding traditional Chinese medicine to standard Western treatments helps reduce side effects and improve quality of life for adult women with breast cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 200 (estimated) |
| Sponsor | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (New Taipei City) |
| Status | Recruiting |
| Started | January 1, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | July 31, 2025 |
| Trial ID | NCT07096180 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult women (age ≥18) with primary breast cancer who are receiving Western cancer treatments and are willing to receive TCM are the intended participants.
✕Probably not a fit
Patients who have other prior malignancies, who are not receiving any Western cancer treatment, or who experience adverse reactions to TCM are unlikely to benefit from this integrated approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective cohort and real-world cross-sectional observational project compares two parallel groups of women with primary breast cancer: one receiving conventional Western oncology care and one receiving combined Western and traditional Chinese medicine (TCM) treatments. Patients choosing TCM are referred to the TCM outpatient clinic for individualized prescriptions and receive ongoing integrated follow-up alongside oncology visits, with both types of care covered by health insurance. Clinical effectiveness is monitored with routine blood tests before treatments and standardized patient-reported questionnaires (including FACT-B, EORTC QLQ-C30/BR23, WHOQOL-BREF and others) before chemotherapy and at regular study visits, with a final evaluation within four weeks after the last radiation or chemotherapy. The study also collects survival status and long-term clinical data to inform enrollment criteria and the practical use of TCM as an adjunctive therapy.
Why it matters
Potential benefit: If successful, the integrated approach could reduce treatment-related side effects and improve patients' quality of life during and after cancer therapy.
How similar studies have gone: Previous studies of TCM as an adjunct to chemotherapy have shown mixed but sometimes promising results for symptom relief and quality-of-life improvements, although evidence is heterogeneous and limited by study design variability.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * A. Aged 18 years or above. * B. Female patients diagnosed with primary breast cancer and receiving Western medical treatment. The included breast cancer diagnosis codes based on ICD-9 are 174 to 179. Exclusion Criteria: * A. Patients with a prior diagnosis of other malignant tumors before being diagnosed with primary breast cancer. * B. Patients with primary breast cancer who have not received Western medical treatment, meaning they have not undergone surgical resection, radiation therapy, chemotherapy, or targeted therapy.. * C. After taking Chinese medicine, those who have uncomfortable symptoms or whose behavior affects Western medicine treatment should withdraw from the trial.
Where it's running
-
Buddhist Taipei Tzu Chi General Hospital
New Taipei City, Taiwan Recruiting
Study contacts
- Principal investigator: Hsien-Chang Wu — Taichung Tzu Chi Hospital
- Study coordinator: Hsien-Chang Wu
- Email: xuang@tzuchi.com.tw
- Phone: 0266289779
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.